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Members of the mannose receptor family, the man-
nose receptor, the phospholipase A2 receptor, DEC-205,
and Endo180, contain multiple C-type lectin-like do-
mains (CTLDs) within a single polypeptide. In addition,
at their N termini, all four family members contain a
cysteine-rich domain similar to the R-type carbohydrate
recognition domains of ricin. However, despite the com-
mon presence of multiple lectin-like domains, these four
endocytic receptors have divergent ligand binding ac-
tivities, and it is clear that the majority of these domains
do not bind sugars. Here the functions of the lectin-like
domains of the most recently discovered family member,
Endo180, have been investigated. Endo180 is shown to
bind in a Ca2-dependent manner to mannose, fucose,
and N-acetylglucosamine but not to galactose. This ac-
tivity is mediated by one of the eight CTLDs, CTLD2.
Competition assays indicate that the monosaccharide
binding specificity of Endo180 CTLD2 is similar to that
of mannose receptor CTLD4. However, additional exper-
iments indicate that, unlike the cysteine-rich domain of
the mannose receptor, the cysteine-rich domain of
Endo180 does not bind sulfated sugars. Thus, although
Endo180 and the mannose receptor are now both known
to be mannose binding lectins, each receptor is likely to
have a distinct set of glycoprotein ligands in vivo.
The mannose receptor family comprises the mannose recep-
tor, the M-type phospholipase A2 receptor, the dendritic cell
receptor DEC-205, and Endo180 (also known as uPARAP) (1–
3). The four members of the family share a common structural
organization. Each receptor is a type I transmembrane receptor
with an extracellular region containing an N-terminal cysteine-
rich domain similar to the galactose-binding domains of ricin, a
fibronectin type II (FNII)1 domain, and either 8 (mannose
receptor, phospholipase A2 receptor, and Endo180) or 10 (DEC-
205) C-type lectin-like domains (CTLDs). The short cytoplas-
mic domain of each receptor mediates internalization of the
receptor into the cell and recycling back to the plasma mem-
brane (4–8). These common features and the fact that the
mannose receptor functions in the clearance of glycoproteins,
initially suggested that a main function of each of these recep-
tors would be to mediate cellular uptake of glycosylated li-
gands. However, although each receptor contains multiple lec-
tin-like domains, the majority of these domains do not bind
sugars.
CTLDs are found in a wide variety of proteins and are char-
acterized by a sequence motif that specifies a conserved fold (9).
They were initially described in C-type lectins such as serum
mannose-binding protein (MBP-A) and the asialoglycoprotein
receptor, which bind sugars in a Ca2-dependent manner.
However, it has become clear that many of these domains lack
the residues required for Ca2-dependent sugar binding and
are thus predicted to have other functions. The majority of
CTLDs within proteins of the mannose receptor family have
not conserved the key amino acids required for coordination of
Ca2 ions and sugar residues, and on this basis none of the
CTLDs within the phospholipase A2 receptor and DEC-205 are
predicted to bind sugar (2, 10) Indeed, sugar binding activity of
DEC-205 has never been demonstrated, and the phospholipase
A2 receptor binds a nonglycosylated protein ligand, phospho-
lipase A2. The mannose receptor does mediate Ca
2-dependent
sugar binding, but this activity appears to be is restricted to
only two of the eight CTLDs (11).
In addition to the CTLDs, all four receptors in the mannose
receptor family contain an N-terminal cysteine-rich domain
with homology to the R-type carbohydrate-recognition domains
found in ricin, some glycosyltransferases, and bacterial hydro-
lases (12). The cysteine-rich domain of the mannose receptor
binds oligosaccharides terminating in GalNAc-4-SO4, such as
those found on the pituitary hormones lutropin and thyrotropin
(13, 14). However, again this activity is unlikely to be shared
with other members of the family. DEC-205 does not bind
lutropin (15), and sequence analysis predicts that the phospho-
lipase A2 receptor and Endo180 will also not bind sulfated
sugars (3, 16).
Endo180 was originally identified in a monoclonal antibody
screen for novel fibroblast cell surface receptors and demon-
strated to be an endocytic recycling glycoprotein (17). Isolation
of murine and human cDNAs revealed it to be the fourth
member of the mannose receptor family (1, 18, 19), and exam-
ination of the human genome sequence suggests that this is the
final family member. In contrast to the phospholipase A2 re-
ceptor and DEC-205, but in common with the mannose recep-
tor, preliminary studies have demonstrated that Endo180 from
cultured cell lysates binds in a Ca2-dependent manner to
immobilized GlcNAc (18). In this study, the roles of the multi-
ple lectin-like domains in sugar binding activity of Endo180
have been investigated using a combination of mutational anal-
ysis and expression of isolated domains.
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EXPERIMENTAL PROCEDURES
Materials—Restriction enzymes and other DNA modifying enzymes
were obtained from New England Biolabs. Nitriloacetic acid-agarose,
monosaccharides, and bovine serum albumin were from Sigma-Aldrich.
Na125I and isopropyl--D-thiogalactoside were from Amersham Bio-
sciences. Mannose30-BSA was purchased from E.-Y. Laboratories and
iodinated by the chloramine-T method (20). Immulon 4 96-well microti-
tre plates were obtained from Dynex Technologies. GlcNAc-, galactose-,
mannose-, and fucose-Sepharose were prepared by the divinyl sulfone
method (21). Lutropin was purified from bovine pituitaries following
the method of Papkoff and Gan (22) and coupled to Affi-Gel 15 (Bio-
Rad). The generation of the human Endo180-specific monoclonal anti-
body A5/158 is described elsewhere (17, 18). Horseradish peroxidase-
conjugated second layer antibodies were purchased from Jackson
Immunoresearch.
Generation and Expression of Endo180-Fc Constructs—The cloning
of Endo180 and generation of the pcDNA3-Endo180 expression con-
struct has been previously described (18). To generate Endo180-Fc
fusion proteins in which the Endo180 was truncated after CTLD4 or
CTLD2 (CTLD5–8-Fc and CTLD3–8-Fc, respectively; see Fig. 1),
PCR was performed with ExpandTM long polymerase (Roche Molecular
Biochemicals) and pcDNA3-Endo180 as a template with a 5 modified
T7 primer (5-CTGGCTTATCGAAATTAATACGACTCACTATAGGGA-
3) and the following 3 primers, 5-GTCTCGAGTTGAGGGCTGTCGT-
CGGGCTCC-3 for CTLD5–8-Fc and 5-GTCTCGAGCCGGCTGCCA-
TGGTCCTCCTCG-3 for CTLD3–8-Fc, where the underlined bases
indicate an XhoI restriction site. Amplified DNA was digested with
HindIII and XhoI and ligated into the pIgplus vector (R & D Systems)
digested with the same enzymes. Mutation of Asn472 to an aspartic acid
residue within CTLD5–8-Fc was generated using the QuikChange™
mutagenesis method (Stratagene) with oligonucleotides 5-GGCACCC-
CTTTGAGCCCGACAAACTTCCGGG-3 and 5-CCCGGAAGTTGTCG-
GGCTCAAAGGGGTGCC-3, where the underlined bases indicate
changes from the wild type sequence. pIgplus-Endo180-Fc constructs
(100 g) were transfected into 50–75% confluent COS-1 cells with 400
g/ml DEAE/dextran, 100 M chloroquine diphosphate in serum-free
Dulbecco’s modified Eagle’s medium. The cells were incubated for 4 h
at 37 °C. The medium was aspirated and replaced with 15 ml of
phosphate-buffered saline with 10% Me2SO osmotic shock medium for
2 min. The osmotic shock medium was replaced with 25 ml of Dulbecco’s
modified Eagle’s medium with 10% fetal calf serum, and the cells were
incubated overnight at 37 °C. 24 h later the medium was replaced with
serum-free Dulbecco’s modified Eagle’s medium. The supernatant was
harvested after a 7-day period.
Expression of Endo180 CTLD2 in Bacteria—The portion of the hu-
man Endo180 cDNA (18) coding for CTLD2 (nucleotides 1259–1651)
was cloned into the expression vector pIN-IIIompA-2 (23) using stand-
ard recombinant DNA techniques. Synthetic oligonucleotides were used
to fuse the 5 end of the cDNA to the codons specifying the ompA signal
sequence and to add a stop codon at the 3 end. The integrity of the final
expression plasmids was checked by DNA sequencing using an ABI
prism 310 Genetic Analyzer. Luria-Bertani medium (1 liter) containing
50 g/ml ampicillin was inoculated with 30 ml of an overnight culture
of Escherichia coli strain JA221 containing the CTLD2 expression plas-
mid. The culture was grown with shaking at 25 °C to an A550 of 1.
Isopropyl--D-thiogalactoside and CaCl2 were then added to final con-
centrations of 50 M and 100 mM, respectively. After growth for a
further 18 h at 25 °C, the cells were harvested by centrifugation at
4,000 rpm for 15 min in a Beckman JS-4.2 rotor. Bacterial pellets were
resuspended in cold 10 mM Tris-HCl, pH 7.8, followed by centrifugation
at 12,000 rpm for 15 min at 4 °C in a Beckman JA14 rotor. The bacteria
were sonicated in 30 ml of 25 mM Tris-HCl, pH 7.8, 0.5 M NaCl, 20 mM
CaCl2 (loading buffer). Lysed bacteria were centrifuged at 10,000  g
for 15 min, and the supernatant was recentrifuged at 100,000  g for
1 h at 4 °C. The supernatant was passed over a 10-ml GlcNAc-Sepha-
rose column equilibrated in loading buffer. The column was washed
with 30 ml of loading buffer and eluted with 10  2 ml of elution buffer
(25 mM Tris-HCl, pH 7.8, 0.5 M NaCl, 2 mM EDTA). Elution fractions
were analyzed by SDS-polyacrylamide gel electrophoresis, and CTLD2
was identified by N-terminal sequencing on a Beckman LF3000 protein
sequencer following transfer to polyvinylidene difluoride membranes.
Fractions containing pure CTLD2 were pooled, and protein was assayed
using the Bio-Rad protein assay reagent with BSA as standard. The
yield of pure CTLD2 ranged from about 0.5 to 1 mg/liter.
Expression of Endo180 Cysteine-rich Domain in Bacteria—The por-
tion of the human Endo180 cDNA (18) coding for the cysteine-rich
domain (nucleotides 236–643) was cloned into the expression vector
pIN-IIIompA-2. Synthetic oligonucleotides were used to fuse the 5 end
of the cDNA to the codons specifying the ompA signal sequence and to
add codons specifying six histidine residues and a stop codon at the 3
end. For protein expression, growth and induction of E. coli strain
JA221 containing the cysteine-rich domain plasmid was as described
above for production of CTLD2, except that no CaCl2 was added at the
time of induction. The bacteria were harvested as described above,
resuspended in 100 ml of N1 buffer (25 mM Tris-HCl, pH 7.8, 0.5 M
NaCl) containing 20 mM imidazole, and lysed by sonication. Lysed
bacteria were centrifuged at 10,000 g for 15 min, and the supernatant
was recentrifuged at 100,000  g for 1 h at 4 °C. The supernatant was
passed down a 1-ml column of nitriloacetic acid-agarose that was pre-
loaded with 5 ml of 50 mM NiSO4 and equilibrated in N1 buffer con-
taining 20 mM imidazole. The column was washed with 10 ml of N1
buffer containing 50 mM imidazole and eluted with N1 buffer containing
150 mM imidazole. Elution fractions were analyzed by SDS-polyacryl-
amide gel electrophoresis, and the cysteine-rich domain was identified
by N-terminal sequencing.
Sugar Binding Assays—For Endo180-Fc chimeras, 100 l of COS-1
tissue culture supernatant in 900 l of loading buffer (150 mM NaCl, 25
mM Tris-HCl, pH 8.0, plus 25 or 10 mM CaCl2) was loaded onto 2-ml
columns of mannose-, GlcNAc-, fucose-, or galactose-Sepharose. The
flow through was collected, and the columns were washed with 7 1 ml
of loading buffer followed by 7  1 ml of elution buffer (150 mM NaCl,
25 mM Tris-HCl, pH 8.0, and 10 mM EDTA). For assay of Endo180 from
Flow2000 fibroblasts, the cells were lysed in 150 mM NaCl, 10 mM
Tris-HCl, pH 8.0, 0.15% Triton X-100, 1 mM MgCl2, 10 mM CaCl2.
Lysate (containing 20 g of protein) was added to 1 ml of loading
buffer containing 0.15% Triton X-100 and applied to the columns. The
columns were washed in loading buffer plus 0.15% Triton X-100 and
eluted in elution buffer plus 0.15% Triton X-100. The fractions were
precipitated by incubation with 40 g of BSA and 0.5 ml of 30% trichlo-
roacetic acid for 30 min on ice and then centrifuged for 10 min at 4 °C
at 15,000  g. The pellets were washed twice in 1:1 ethanol ether, air
dried for 10 min, and resuspended in 40 l of nonreducing sample
buffer. The samples (10 l) were resolved by 10% SDS-polyacrylamide
gel electrophoresis and transferred to nitrocellulose, and Endo180 was
detected using monoclonal antibody A5/158 followed by horseradish
peroxidase-conjugated anti-mouse immunoglobulin. The blots were de-
veloped using ECL reagent (Amersham Biosciences).
Sugar Competition Assays—Plastic microtitre plates with removable
wells (Immulon 4) were coated with CTLD2 (50 l/well of a 100 g/ml
solution of CTLD2 in 25 mM Tris-HCl, pH 7.8, 0.1 M NaCl, 25 mM
CaCl2). Following incubation overnight at 4 °C, the wells were washed
three times with cold washing buffer (25 mM Tris-HCl, pH 7.8, 0.1 M
NaCl, 25 mM CaCl2). Nonspecific binding sites were blocked by filling
the wells with 5% (w/v) BSA in washing buffer and incubating for 2 h at
4 °C. After washing the wells three times with cold washing buffer,
aliquots (100 l) of a range of concentrations of monosaccharide in
washing buffer containing 125I-Man-BSA (1 g/ml) and 5% BSA were
added to the wells in duplicate. Following incubation at 4 °C for 2 h, the
wells were washed three times with cold washing buffer and counted on
a  counter. The values for Ki (the inhibitor concentration that gives
50% inhibition of 125I-Man-BSA binding) for each inhibitor were deter-
mined by fitting the data to the following equation for simple compet-
itive inhibition: fraction of maximal binding  KI/(KI  [Inhibitor]).
RESULTS
Localization of Ca2-dependent Sugar Binding Activity of
Endo180 to CTLD2—Previous studies have demonstrated that
Endo180 solubilized from cultured cells displays Ca2-depend-
ent binding to immobilized GlcNAc (18). Sequence analysis
predicts that this activity is likely to be mediated by CTLD2
because it is the only Endo180 CTLD that contains all of the
five residues that ligate two hydroxyl groups of a monosaccha-
ride and a Ca2 in other sugar-binding CTLDs (Fig. 1). In
addition, the presence of the sequence EPN (amino acids 470–
472) at the position equivalent to the principal Ca2-binding
site of MBP-A and other mannose-specific C-type lectins pre-
dicts that Endo180 CTLD2 will ligate sugars with equatorial
three and four hydroxyl groups, including GlcNAc and man-
nose (24). To define the roles of the different domains of
Endo180 and to investigate further the specificity of the recep-
tor, the sugar binding activity of several different Endo180
expression constructs has been assessed.
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Soluble Endo180 constructs were generated as chimeric
proteins fused to the Fc portion of human Ig. The presence of
the Fc tail enables detection using anti-human Fc antibodies
and, if required, purification of constructs on protein G col-
umns. Endo180-Fc constructs were expressed in COS-1 cells
and tested for their ability to bind to immobilized monosac-
charides. In these assays, monosaccharide-Sepharose col-
umns were loaded with expressed Endo180-Fc protein in
Ca2-containing buffer. After washing with the Ca2-
containing buffer, the columns were eluted with buffer con-
taining EDTA to detect proteins bound to the column in a
Ca2-dependent manner. For initial studies, an Fc chimera
containing Endo180 deleted after CTLD4 (Endo180CTLD5–
8-Fc; Fig. 2) was employed. A significant fraction of this
Endo180-Fc construct is retained on columns of GlcNAc-,
mannose-, and fucose-Sepharose but not on galactose-
Sepharose and is eluted in the presence of EDTA (Fig. 3A).
The results indicate that Endo180 has specificity for man-
nose and fucose as well as GlcNAc and that CTLDs 5–8 are
not required for Ca2-dependent binding of these
monosaccharides.
In a previous, preliminary study of sugar binding by
Endo180, only binding to immobilized GlcNAc and not to im-
mobilized mannose and fucose was detected (18). This apparent
selectivity for GlcNAc was somewhat surprising because C-
type lectins that bind GlcNAc, including the mannose receptor
and MBP-A, generally bind mannose and fucose as well (24).
The discrepancy in these data does not result from the use in
this current study of chimeric constructs that are dimerized via
their Fc tails because native Endo180 from Flow2000 cell ly-
sates was also demonstrated to bind to mannose-Sepharose
(Fig. 3B), and identical binding profiles were obtained with a
soluble Endo180 construct generated without an Fc tail (data
not shown). Differences in the monosaccharide resins used are
the most likely explanation for the difference between the
results obtained here and those reported previously (18). In
this study, monosaccharides were conjugated to Sepharose in
the laboratory using a procedure that has been used to produce
resins for study of sugar binding by other C-type lectins. It is
likely that these resins contain a higher ratio of attached sugar
compared with the commercial monosaccharide-agarose matri-
ces used previously and consequently provide more effective
substrates for lectin binding.
Analysis of an Endo180-Fc chimera deleted after CTLD2
(Endo180CTLD3–8-Fc; Fig. 2) indicates that CTLDs 3 and 4
are also not required for Ca2-dependent sugar binding. Like
the construct deleted after CTLD4, this truncated construct
binds to mannose-Sepharose (Fig. 4A) and GlcNAc-Sepharose
(data not shown).
The involvement of Endo180 CTLD2 in sugar binding was
assessed further by mutation of key residues in Ca2 site 2. In
the first construct, Glu470 and Asn492 (Fig. 1) were each
changed to alanine. However, this protein could not be ex-
pressed, suggesting that these two residues are required for the
correct folding and stability of CTLD2. Because this unstable
protein could not be assessed for sugar binding, a second con-
struct was generated in which Asn472, another of the residues
predicted to be involved in ligation of sugar and Ca2 to
CTLD2, was mutated. In MBP-A and E-selectin, the amide
nitrogen of the equivalent asparagine residue forms a hydrogen
bond to a sugar hydroxyl group, whereas the carbonyl oxygen
forms a coordination bond with the Ca2 ion that is also ligated
to the sugar. Mutation of this Asn residue to Asp in the CTLDs
of MBP-A (25) and E-selectin (26) abolishes sugar binding
activity because of a loss of the hydrogen bond to the sugar
hydroxyl group. Asn472 in CTLD2 was mutated to aspartic acid
in the context of the Endo180-Fc chimera containing Endo180
deleted after CTLD4 (Endo180CTLD5–8(N472D)-Fc; Fig. 2).
Binding of the mutated Endo80 construct to mannose-Sepha-
rose is observed in the presence of 25 mM Ca2, but this binding
FIG. 2. Diagram of Endo180 constructs. Wild type Endo180 pro-
tein has an N-terminal cysteine-rich domain (cys) followed by a FNII
domain and eight CTLDs. Soluble constructs were generated in which
Endo180 truncated after CTLD4 (Endo180CTLD5–8-Fc) or after
CTLD2 (Endo180CTLD3–8) was fused in frame with the Fc portion of
human IgG. These constructs were expressed in COS-1 cells. CTLD2
and the cysteine-rich domain with a C-terminal His tag were expressed
in bacteria. The N-terminal signal sequences are not shown.
FIG. 1. Sequence comparisons of C-type lectin-like domains. The CTLD of MBP-A is aligned with human Endo180 CTLD1 and CTLD2
(Endo180 (1) and Endo180 (2), respectively) and mannose receptor CTLD4 (MR (4)). Conserved residues that define the CTLD fold and the Ca2
sites are shaded in gray and black, respectively (46, 47). 1 and 2 denote residues involved in ligating two Ca2 (Ca2 1 and Ca2 2) to MBP-A. The
binding site for Ca2 site 2, also known as the principal Ca2, is conserved in all sugar-binding CTLDs. The auxiliary Ca2 site 1 is conserved in
some sugar binding CTLDs. x, aliphatic or aromatic; , aliphatic; o, aromatic; *, side chain with carbonyl oxygen; Z, E or Q; B, D or N. Invariant
amino acids are shown in single-letter codes.
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is reduced compared with the wild type construct (Fig. 4B).
However, at 10 mM Ca2, the mutated construct does not bind
to mannose-Sepharose, whereas binding of the wild type con-
struct is not affected by the reduction in Ca2 concentration
(Fig. 4B). Similar results were obtained when the constructs
were tested on GlcNAc-Sepharose (data not shown). The assays
were initially carried out at 25 mM Ca2, because this concen-
tration has typically been used for assaying other C-type lec-
tins and C-type carbohydrate recognition domains (25, 27–29).
Measured affinities of C-type carbohydrate recognition do-
mains for Ca2 are in the range 0.2–1.0 mM, and as long as
Ca2 is saturating, varying Ca2 concentration does not affect
sugar binding (29–31). Thus, the fact that the mutated
Endo180(N472D) construct shows no sugar binding activity at
10 mM Ca2 indicates that the Ca2 binding affinity of CTLD2
has been substantially reduced by the mutation and that the
mutated construct would not have sugar binding activity at
physiological Ca2 concentration. These results indicate that
Asn472 of CTLD2 is likely to be involved in ligation of sugar and
Ca2 and that CTLD2 is responsible for the sugar binding
activity of the Endo180 construct deleted after CTLD4.
Monosaccharide Binding Activity of Endo180 CTLD2—The
experiments with deletion constructs give a strong indication
that CTLD2 is the domain responsible for mediating Ca2-de-
pendent binding of mannose, GlcNAc, and fucose to Endo180.
To allow direct assessment of sugar binding activity by CTLD2,
this domain was expressed in bacteria using an expression
system that has been successful for producing other C-type
domains (27, 29). The CTLD is expressed as a fusion protein
with the ompA signal sequence, which directs the protein into
the periplasm where conditions are favorable for folding. Ex-
pressed CTLD2 was purified from the bacterial lysate by affin-
ity chromatography on GlcNAc-Sepharose. Like the
Endo180-Fc construct truncated after CTLD4, isolated CTLD2
binds to GlcNAc-, mannose-, and fucose-Sepharose in a Ca2-
dependent manner but does not bind to galactose-Sepharose
(Fig. 5).
The specificity of CTLD2 was further investigated using a
competition assay in which monosaccharides compete for bind-
ing of 125I-Man30-BSA to immobilized CTLD2. Unlike the col-
umn binding assays, which can only give a qualitative indica-
tion of specificity, this assay allows quantitative assessment of
binding of different monosaccharides to CTLD2. Representa-
tive inhibition curves are shown in Fig. 6, with inhibition
constants given in Table I. In agreement with the results ob-
tained with monosaccharide resins, mannose, GlcNAc, and fu-
cose are effective inhibitors of 125I-Man30-BSA binding to
CTLD2. The weak inhibition seen with galactose is likely to be
due to interaction with the anomeric hydroxyl of the free sugar,
because -methylgalactoside does not inhibit binding of 125I-
Man30-BSA. Such nonphysiological binding of galactose has
been seen with other mannose-specific C-type lectins (28, 32).
The results suggest that Endo180 CTLD2 distinguishes be-
tween monosaccharides in a manner similar to that of other
C-type lectins through recognition of the C-3 and C-4 hydroxyls
and that like other mannose-specific C-type lectins, CTLD2
binds preferentially to sugars with equatorial C-3 and C-4
hydroxyl groups. Mannose, glucose, GlcNAc, and N-acetylman-
FIG. 3. Specificity of Endo180 binding to immobilized mono-
saccharides. Tissue culture supernatant containing Endo180CT-
LD5–8-Fc construct (A) or Flow2000 cell lysate (B) was loaded onto
GlcNAc-, mannose-, fucose-, or galactose-Sepharose columns. The colu-
mns were washed with loading buffer (containing 25 mM Ca2) and then
elution buffer. The fractions (Wash 1–7 and Elute 1–7) were analyzed by
Western blotting as described under “Experimental Procedures.” Note
that the increased size of the Fc construct results from Fc-mediated
dimerization on nonreducing SDS-polyacrylamide gel electrophoresis.
FIG. 4. Mutation of Asn472 in Endo180 CTLD2 impairs binding
to mannose. Tissue culture supernatant containing Endo180CT-
LD3–8-Fc (A) or containing Endo180CTLD5–8-Fc or Endo180CT-
LD5–8(N472D)-Fc (B) were loaded onto mannose-Sepharose columns
and analyzed as described in the legend to Fig. 2 except that loading
buffers contained either 25 or 10 mM Ca2.
FIG. 5. Binding of isolated Endo180 CTLD2 to monosaccharide
columns. Purified CTLD2 in 1 ml of loading buffer was passed over
2-ml columns of GlcNAc-, fucose-, mannose-, and galactose-Sepharose.
The columns were washed with 7  1 ml of loading buffer and eluted
with 8  1 ml of elution buffer. The flow through (F) and all fractions
(Wash 1–7 and Elute 1–8) were analyzed by SDS-polyacrylamide gel
electrophoresis on 17.5% gels that were stained with Coomassie Blue.
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nosamine are approximately equal in effectiveness as inhibi-
tors of 125I-Man30-BSA binding, suggesting that substituents
at the C-2 position do not interact significantly with Endo180
CTLD2. Fucose, which can bind to mannose-specific C-type
lectins through equatorial hydroxyl groups on C-2 and C-3,
interacts with CTLD2 as strongly as mannose. Thus, Endo180
CTLD2 binds the same range of monosaccharides as other
mannose-specific C-type lectin domains.
The Cysteine-rich Domain of Endo180 Does Not Bind Sul-
fated Sugars—Like the other members of the mannose family,
Endo180 has an N-terminal cysteine-rich domain homologous
to the galactose-binding R-type carbohydrate recognition do-
mains of ricin. However, the cysteine-rich domain of Endo180
does not contain the residues that interact with galactose in
ricin, nor the residues that interact with GalNAc-4-SO4 in the
mannose receptor cysteine-rich domain and is thus not pre-
dicted to have sugar binding activity (3, 16). The Endo180
cysteine-rich domain was produced in bacteria so that its sugar
binding activity could be assessed. As for CTLD2, the cysteine-
rich domain was expressed as a fusion protein with the ompA
signal sequence, so that it was directed into the bacterial
periplasm. Mannose receptor cysteine-rich domain produced
in the same way folds correctly and can be purified from
the bacterial lysate by affinity chromatography on
lutropin-agarose.2
Endo180 cysteine-rich domain with a C-terminal His tag was
purified by nickel affinity chromatography and tested for its
ability to bind to lutropin-agarose. Analysis of the lutropin-
agarose column fractions demonstrates that none of the
Endo180 cysteine-rich domain is retained on the column (Fig.
7A). In contrast, although a small fraction of the mannose
receptor cysteine-rich domain is detected in the wash fractions,
most binds to the lutropin column and is slowly eluted with the
low pH elution buffer (Fig. 7B). Thus, as predicted from the
sequence analysis, the cysteine-rich domain of Endo180 does
not contain a binding site for GalNAc-4-SO4. The cysteine-rich
domain of Endo180 also does not bind to Gal- or GlcNAc-
Sepharose (data not shown), indicating that this domain does
not contribute to the sugar binding activity of the receptor.
DISCUSSION
A combination of deletion mutagenesis and expression of
isolated domains of Endo180 has defined the roles of individual
domains of this receptor in sugar binding. Like the mannose
receptor, Endo180 binds mannose, GlcNAc, and fucose in a
Ca2-dependent manner, and this activity is associated with a
single CTLD. However, unlike the mannose receptor, Endo180
lacks a binding site for sulfated sugars in the cysteine-rich
domain.
Ca2-dependent binding of mannose, GlcNAc, and fucose to
Endo180 is mediated by CTLD2. It is likely that the mecha-
nism of sugar binding by this domain is similar to other man-
nose-specific CTLDs and involves ligation of two equatorial
hydroxyl groups of a monosaccharide by two pairs of aspara-
gine and glutamic acid residues at the conserved principal
Ca2 site (25). In the mannose receptor, a single CTLD is also
mainly responsible for mediating Ca2-dependent binding to a
similar range of monosaccharides, but in this case it is CTLD4
rather than CTLD2 (11). Interestingly, although the phospho-
lipase A2 receptor does not bind sugars, a single CTLD of this
receptor, CTLD5, is also largely responsible for the Ca2-inde-
pendent binding to nonglycosylated secretary phospholipases
A2 (33).
Although it is clear that CTLD2 is largely responsible for
sugar binding by Endo180, the possibility that an additional
CTLD may be involved in binding glycoprotein ligands, as is
the case in the mannose receptor, should be considered. Only
CTLD4 of the mannose receptor binds sugars when expressed
in isolation, but the five residues that ligate the principal Ca2
are also absolutely conserved in CTLD5, and there is strong
evidence that CTLD5 contributes to binding of natural glyco-
proteins to the receptor (11, 34). However, in Endo180, no other
CTLD apart from CTLD2 contains all of the residues required2 C. T. Heise and M. E. Taylor, unpublished observations.
FIG. 6. Inhibition of 125I-Man30-BSA binding to Endo180 CTLD2
by monosaccharides. The data were obtained using the competition
assay. The experimental values (symbols) are shown together with the
theoretical curves (lines) fitted to the data.
TABLE I
Monosaccharide binding by Endo180 CTLD2
Inhibition constants for each monosaccharide were determined using
the competition assay. The results are presented as the means S.D. of
3–5 assays done in duplicate.
Monosaccharide Ki Ki Sugar/Ki Man
mM
Mannose 1.8  0.1 1
N-Acetylglucosamine 2.3  0.1 1.28
L-Fucose 1.6  0.1 0.89
Glucose 2.6  0.7 1.44
-Methylmannoside 2.0  0.6 1.11
N-Acetylmannosamine 2.2  0.9 1.22
Galactose 22.7  2.3 12.6
-Methylgalactoside 	400 	200
FIG. 7. Endo180 cysteine-rich domain does not bind sulfated
sugars. Purified cysteine-rich domain in 1 ml of 20 mM Tris-HCl, pH
7.4, 100 mM NaCl (washing buffer) was passed over a 2-ml column of
lutropin-agarose. The column was washed with 8  1 ml of washing
buffer and eluted with 10  1 ml of 25 mM glycine, pH 2.5, 0.5 M NaCl.
The fractions (Wash 1–8 and Elute 1–10) and a sample of the starting
material loaded onto the column (S) were analyzed by SDS-polyacryl-
amide gel electrophoresis on 17.5% gels that were stained with Coo-
massie Blue. A, Endo180 cysteine-rich domain. B, mannose receptor
cysteine-rich domain.
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for ligating Ca2 and sugar. CTLD1 contains several of these
residues, but Gln and Asn replace Asn and Asp of the conserved
WND sequence (Asn205 and Asp206 in MBP-A) (Fig. 1). Thus,
Ca2 and sugar could not be ligated at this site in exactly the
same way as in known sugar-binding CTLDs. In addition, the
presence of the sequence QPD (amino acids 326–328) rather
than EPN predicts that CTLD1 would be more likely to bind
galactose-like rather than mannose-like monosaccharides (24).
The fact that neither intact Endo180 nor any of the deletion
constructs containing CTLD1 bind to galactose-Sepharose sug-
gests that there is unlikely to be any interaction of this domain
with galactose. However, the possibility that CTLD1 contrib-
utes to binding of natural ligands to Endo180 in a manner
similar to that of CTLD5 of the mannose receptor cannot be
absolutely ruled out.
The finding that Endo180 exhibits Ca2-dependent binding
to a similar spectrum of monosaccharides as the mannose re-
ceptor is of interest because it raises the possibility that these
two receptors might have some overlap in function, particularly
as they are both expressed on macrophages (18, 35). The main
role of the mannose receptor appears to be in the clearance of
proteins bearing high mannose oligosaccharides, such as lyso-
somal enzymes that are released as part of the inflammatory
response (36). Endocytic activity of Endo180 has been well
characterized (8, 17), and given the results presented here it is
likely that this receptor will also mediate uptake of glycopro-
teins. However, several lines of evidence suggest that there will
probably be only limited, if any, overlap in the ligands and
functions of these two receptors in vivo.
The sugar binding CTLDs of Endo180 and the mannose
receptor are located in different positions relative to the other
domains in the protein, and this difference is likely to affect the
interactions of the two proteins with glycoprotein ligands. Hy-
drodynamic analysis and protease resistance studies reveal
that the extracellular region of the mannose receptor adopts a
relatively rigid extended conformation with the cysteine-rich
domain projected furthest from the membrane. In addition
there are close interactions between the domains with the
exception that the linker regions on either side of CTLD3 and
CTLD6 are flexible and exposed (37). Thus, CTLD4 and CTLD5
are in close contact with each other, but are separated from the
neighboring domains, and form a ligand-binding core in the
middle of the polypeptide. This arrangement is likely to be
important for binding multiple mannose residues on high man-
nose oligosaccharides. If, as is likely, the conformation of the
extracellular region of Endo180 is similar to that of the man-
nose receptor, then Endo180 CTLD2 will be projected further
from the membrane and may be accessible to glycoprotein
ligands that cannot bind to the mannose receptor. In addition,
the Endo180 cysteine-rich domain, the FNII domain, CTLD1,
and CTLD2 will be closely associated and separated from
CTLD3. Thus, sugar binding to CTLD2 may be modulated by
the close proximity of CTLD1 and additionally by the FNII
domain, especially if, like FNII domains found in several other
proteins, this domain has a role in collagen binding (3).
Endo180 and the mannose receptor also have distinct pat-
terns of expression. Although both are expressed on macro-
phages (18, 35), Endo180 is also found on fibroblasts and chon-
drocytes, chondrocytes, a subset of endothelial cells, and in
tissues undergoing ossification (1, 17, 18, 38–40), whereas the
mannose receptor has been detected on lymphatic and hepatic
endothelium, smooth muscle cells, and some epithelia (41–44).
These differences in distribution may reflect accessibility to
distinct sets of ligands in vivo.
Finally, evidence is presented here that the Endo180 cys-
teine-rich domain does not bind sugars. In contrast, the equiv-
alent domain of the mannose receptor binds sulfated GalNAc
found on the oligosaccharides of soluble glycoproteins such as
lutropin (13), as well as sulfated Lewis blood group antigens
and chondroitin 4-sulfate groups of proteoglycans (15). The
mannose receptor cysteine-rich domain can also mediate asso-
ciation with transmembrane glycoproteins bearing sulfated oli-
gosaccharides, including sialoadhesin and CD45 (45). Conse-
quently Endo180, unlike the mannose receptor, will not
function in the uptake of soluble glycoproteins or extracell-
ular matrix components bearing sulfated sugars nor act as a
counter-receptor for transmembrane proteins with sulfated
oligosaccharides.
Further understanding of the function of Endo180 will re-
quire the identification of natural glycoprotein ligands. Type V
collagen and a complex of the pro form of urokinase-type plas-
minogen activator and its receptor have been identified as
potential ligands for Endo180 (19). Little is yet known about
the molecular basis for these interactions, but each of these
molecules is glycosylated, raising the possibility that recogni-
tion of sugars could be involved.
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